Furthermore, it has been confirmed that inhibition of β-catenin signaling in HCC improve the activation of specific T cells, promoting their infiltration into the tumor microenvironment and preventing CD8+ T-cell exhaustion following an initial response to anti-PD-1 therapy. This evidence concerns the gene CD8A and neoplasm.